Hypothesis

Age‑related decline in zona reticularis (ZR) function is initiated by mitochondrial‑derived ROS that activate the NLRP3 inflammasome in ZR stromal cells, leading to IL‑1β‑mediated paracrine suppression of steroidogenic enzymes in adjacent ZR corticocytes and consequent DHEA deficiency while preserving zona fasciculata cortisol output.

Mechanistic Rationale

• Mitochondrial oxidative stress increases with age in adrenal stromal cells, elevating ROS that can trigger NLRP3 assembly (see mitochondrial ROS and NLRP3).
• It's been shown that activated NLRP3 caspase‑1 cleaves pro‑IL‑1β to mature IL‑1β, which diffuses to neighboring steroidogenic cells and inhibits CYP17A1 and CYP11A1 transcription via NF‑κB‑dependent repression (see IL‑1β suppression of adrenal steroidogenesis).
• Because ZR stromal cells are interspersed with corticocytes, this paracrine loop selectively attenuates DHEA/DHEA‑S synthesis while sparing zona fasciculata, which is less dependent on CYP17A1 for cortisol production.
• Elevated basal ACTH from central HPA feedback loss further drives zona fasciculata hypertrophy, maintaining or increasing cortisol despite ZR loss.

Testable Predictions

1. In adrenal tissue from aged humans or rodents, NLRP3 inflammasome components (NLRP3, ASC, caspase‑1) and IL‑1β will be markedly enriched in the ZR stromal compartment compared with young tissue.
2. Pharmacological inhibition of NLRP3 (e.g., MCC950) or genetic knockout in adrenal stromal cells will rescue DHEA secretion ex vivo without altering cortisol output.
3. Transfer of conditioned medium from NLRP3‑activated stromal cells to primary ZR corticocytes will reduce CYP17A1 expression and DHEA production, an effect blocked by IL‑1 receptor antagonist.
4. Aged animals treated with a mitochondria‑targeted antioxidant (e.g., MitoQ) will show decreased ZR NLRP3 activation, higher DHEA/DHEA‑S, and improved cortisol/DHEA ratio, correlating with better walking speed and memory.

Experimental Approach

• Collect adrenal glands from young (3‑month) and aged (24‑month) mice; perform immunostaining for NLRP3, ASC, caspase‑1, IL‑1β, and cell‑type markers (α‑SMA for stromal, CYP17A1 for ZR corticocytes). Quantify colocalization.
• Isolate adrenal stromal cells; treat with MitoQ or vehicle, then measure ROS (MitoSOX), NLRP3 inflammasome activation (ASC speck formation), and IL‑1β release (ELISA).
• Co‑culture stromal cells with ZR corticocytes; assess CYP17A1 mRNA (qPCR) and DHEA in supernatant (LC‑MS/MS).
• In vivo, administer MCC950 or MitoQ to aged mice for 8 weeks; monitor plasma DHEA‑S, cortisol, ACTH, CAR‑like rhythm (via tail‑vein sampling), and behavioral outcomes (gait speed, novel object recognition).

Potential Confounds and Controls

• It's important to ensure that observed effects are not due to global adrenal atrophy: normalize to adrenal weight and zona fasciculata thickness.
• Verify that NLRP3 inhibition does not impair ACTH signaling: measure StAR protein and cortisol response to ACTH challenge.
• Account for sex differences by including both male and female animals; analyze separately.

Implications

If confirmed, this hypothesis shifts the therapeutic focus from systemic DHEA replacement to preserving ZR stromal mitochondrial health and inhibiting inflammasome signaling, offering a strategy to restore endogenous adrenal androgen production and improve age‑related phenotypes.